For example, dysregulated expression of AKR1B10 in hepatocellular Carcinoma (26), breast cancer (27), and colorectal cancer (28) make AKR1B10 inhibitors as potential drugs for cancer treatment (29). This evidence concerns the gene AKR1B10 and breast cancer.